Table 1.
Comparison of baseline patient characteristics between those with or without early PD to atezolizumab and bevacizumab
| All patients (N = 68) | PD after 6 weeks (N = 13) | Non-PD after 6 weeks (N = 55) | p value | |
|---|---|---|---|---|
| Age (range), years | 72 (31–89) | 75 (37–83) | 70 (31–89) | 0.85 |
| Sex | ||||
| Male | 55 | 10 | 45 | 0.70 |
| Female | 13 | 3 | 10 | |
| Etiology | ||||
| Viral hepatitis | 30 | 4 | 26 | 0.36 |
| NBNC | 38 | 9 | 29 | |
| CH | 33 | 9 | 24 | 0.13 |
| LC | 35 | 4 | 31 | |
| ECOG PS | ||||
| 0 | 54 | 10 | 44 | >0.99 |
| 1 | 14 | 3 | 11 | |
| White blood cell count, mm3 | 5,040 (1,970–11800) | 4,800 (2700–11800) | 5,200 (1,970–11800) | 0.91 |
| Neutrophil count, mm3 | 3,285 (1,185–9,971) | 2760 (1,809–9,971) | 3,440 (1,185–9,204) | 0.84 |
| Lymphocyte count, mm3 | 1,120 (140–2881) | 1,296 (540–2366) | 1,088 (140–2881) | 0.41 |
| NLR | 2.83 (0.83–16.69) | 2.20 (0.83–7.52) | 2.98 (0.98–16.69) | 0.32 |
| Platelet, ×104/µL | 16.7 (3.6–46.4) | 16.8 (8.5–32.6) | 16.2 (3.6–46.4) | 0.79 |
| Prothrombin time, % | 95.9 (35.3–128.0) | 103.3 (81.8–113.8) | 95.0 (35.3–128.0) | 0.10 |
| NH3, µg/dL | 42 (8–136) | 30 (12–100) | 43 (8–136) | 0.24 |
| Albumin, g/dL | 3.7 (2.7–4.8) | 3.9 (3.1–4.8) | 3.7 (2.7–4.8) | 0.48 |
| ALBI grade | ||||
| 1 | 25 | 5 | 20 | 0.85 |
| 2a | 23 | 5 | 18 | |
| 2b | 20 | 3 | 17 | |
| AST, IU/L | 45 (14–672) | 44 (20–134) | 46 (14–672) | 0.72 |
| ALT, IU/L | 28 (7–278) | 35 (12–122) | 27 (7–278) | 0.53 |
| Child-Pugh grade | ||||
| A | 65 | 13 | 52 | >0.99 |
| B | 3 | 0 | 3 | |
| Child-Pugh score | ||||
| 5 | 38 | 9 | 29 | 0.67 |
| 6 | 27 | 4 | 23 | |
| 7 | 1 | 0 | 1 | |
| 8 | 2 | 0 | 2 | |
| AFP, ng/mL | 111.8 (0.8–200000.0) | 156.0 (2.4–15009.5) | 80.1 (0.8–200000.0) | 0.67 |
| DCP, mAU/mL | 887 (19–245000) | 839 (25–110159) | 1,116 (19–245000) | 0.59 |
| Maximum intrahepatic tumor size, mm | 32.0 (0–166.6) | 21.6 (0–119) | 36 (0–166.6) | 0.39 |
| More than 50% liver involvement | 11 | 2 | 9 | >0.99 |
| Diffuse type | 10 | 1 | 9 | 0.67 |
| Hepatic tumors | ||||
| 0 | 10 | 2 | 8 | 0.94 |
| 1 | 7 | 1 | 6 | |
| Multiple | 51 | 10 | 41 | |
| BCLC stage | ||||
| B | 23 | 6 | 17 | 0.34 |
| C | 45 | 7 | 38 | |
| Up to seven | ||||
| In | 23 | 4 | 19 | >0.99 |
| Out | 45 | 9 | 36 | |
| Positive for Vp | 13 | 3 | 10 | 0.70 |
| Positive for Vv | 1 | 0 | 1 | >0.99 |
| Positive for bile duct invasion | 1 | 0 | 1 | >0.99 |
| Positive for LN metastasis | 13 | 1 | 12 | 0.44 |
| Positive for EHM | 31 | 4 | 27 | 0.35 |
| Naive | 16 | 3 | 13 | >0.99 |
| Recurrence | 52 | 10 | 42 | |
| History of operation | 33 | 8 | 25 | 0.36 |
| History of RFA | 19 | 3 | 16 | >0.99 |
| History of TACE | 29 | 7 | 22 | 0.53 |
| History of HAIC | 1 | 0 | 1 | >0.99 |
| History of RT | 10 | 1 | 9 | 0.67 |
| History of TKI | 39 | 9 | 30 | 0.37 |
NBNC, non-HBV non-HCV; CH, chronic hepatitis; LC, liver cirrhosis; ECOG PS, Eastern Cooperative Oncology Group Performance Status; BMI, body mass index; NLR, neutrophil to lymphocyte ratio; ALBI, albumin-bilirubin; AST, aspartate aminotransferase; ALT alanine aminotransferase; AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin; BCLC, Barcelona Clinic Liver Cancer; LN, lymph node; EHM, extrahepatic metastasis; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; RT, radiation therapy; TKI, tyrosine kinase inhibitor